Naltrexone Implant for Opioid Use Disorder
Amber N Edinoff1, Catherine A Nix1, Claudia V Orellana1
1Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA.
Neurology International
|January 25, 2022
Summary
Naltrexone shows promise for treating opioid use disorder (OUD). Long-acting implants may improve compliance and reduce relapse rates compared to oral formulations, offering a novel OUD treatment.
Area of Science:
- Addiction Medicine
- Pharmacology
- Public Health
Background:
- The opioid crisis remains a significant public health concern in the U.S.
- Opioid Use Disorder (OUD) treatment has evolved since the 1960s.
- Naltrexone, an opioid antagonist, offers a non-addictive treatment option for OUD.
Purpose of the Study:
- To evaluate the efficacy and safety of naltrexone for treating Opioid Use Disorder (OUD).
- To compare oral naltrexone with long-acting injectable formulations for OUD treatment outcomes.
- To assess the impact of naltrexone on mental health and patient compliance.
Main Methods:
- Review of studies comparing oral naltrexone to other OUD treatments.
- Analysis of compliance rates and relapse data for oral vs. implant naltrexone.
- Examination of naltrexone's effects on anxiety, depression, and anhedonia.
Main Results:
- Oral naltrexone shows effectiveness but is limited by short treatment durations and poor compliance.
- Long-acting naltrexone implants demonstrate higher compliance and slower return to use rates.
- Naltrexone treatment did not worsen mental health symptoms and may reduce hospitalizations.
Conclusions:
- Short treatment duration is a key factor in poor outcomes with oral naltrexone.
- Long-acting naltrexone implants present a promising, potentially more effective, treatment for OUD.
- Naltrexone implants may offer a novel therapeutic strategy for managing opioid addiction.
More Related Videos
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
5.4K
13:27A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
Published on: October 6, 2018
8.2K
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
484
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
484
01:22Opioid Receptors: Overview
2.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.2K
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
434
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
434
01:17Drugs for Treatment of Diarrhea-Predominant IBS
347
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
347
01:25Analgesia and Pain Management
896
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
896
01:17Drug Dependence
1.2K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.2K